EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer

Osimertinib is the latest generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor used for patients with EGFR-mutated non-small cell lung cancer (NSCLC). We aimed to explore the novel mechanisms of osimertinib by particularly focusing on EGFR-independent effects, which have not...

Descripción completa

Detalles Bibliográficos
Autores principales: Nanamiya, Ren, Saito-Koyama, Ryoko, Miki, Yasuhiro, Inoue, Chihiro, Asavasupreechar, Teeranut, Abe, Jiro, Sato, Ikuro, Sasano, Hironobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395224/
https://www.ncbi.nlm.nih.gov/pubmed/34445227
http://dx.doi.org/10.3390/ijms22168522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395224/
https://www.ncbi.nlm.nih.gov/pubmed/34445227
http://dx.doi.org/10.3390/ijms22168522

Ejemplares similares